Related Experiment Video

Updated: Nov 3, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

744

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Hao Zhang1, Ziyu Dai1, Wantao Wu2

  • 1Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.

Journal of Experimental & Clinical Cancer Research : CR
|June 5, 2021
PubMed

Insights

Immune checkpoints like CTLA-4 and PD-1 regulate T cell function in cancer. Understanding their regulation is key to improving immunotherapy effectiveness and patient outcomes.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)/B7 and programmed death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) are critical immune checkpoints.
  • These pathways negatively regulate T cell activation, impacting cancer immunotherapy.
  • While combined therapies show promise, only a subset of patients benefit from prolonged survival.

Purpose of the Study:

  • To review the regulatory mechanisms of PD-L1 and CTLA-4.
  • To explore the interplay between PD-L1 and CTLA-4 in immunotherapy.
  • To identify strategies for improving patient selection and clinical care.

Main Methods:

  • Discussion of PD-L1 and CTLA-4 regulation at DNA, RNA, and protein levels.
  • Analysis of indirect regulatory factors including biomarkers and cellular localization.
  • Review of existing and potential therapeutic drugs targeting these pathways.

Main Results:

  • Regulation of PD-L1 and CTLA-4 expression significantly influences immunotherapy outcomes.
  • In-depth understanding of their interplay can guide patient stratification.
  • Development of novel drugs targeting PD-L1 and CTLA-4 offers potential for enhanced efficacy.

Conclusions:

  • Targeting CTLA-4 and PD-1 pathways has transformed cancer immunotherapy.
  • Further research into the complex regulation of PD-L1 and CTLA-4 is crucial.
  • Optimizing immunotherapy requires a deeper understanding of these immune checkpoints to improve patient responses and survival.
Keywords:
CTLA-4Cancer immunotherapyDrug interventionPD-L1Regulatory mechanism

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

906
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
791
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K